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Abstract The glyoxalase system in the cytoplasm of
cells provides the primary defence against glycation by
methylglyoxal catalysing its metabolism to D-lactate.
Methylglyoxal is the precursor of the major quantitative ad-
vanced glycation endproducts in physiological systems - argi-
nine-derived hydroimidazolones and deoxyguanosine-derived
imidazopurinones. Glyoxalase 1 of the glyoxalase system was
linked to anthropometric measurements of obesity in human
subjects and to body weight in strains of mice. Recent confer-
ence reports described increased weight gain on high fat diet-
fed mouse with lifelong deficiency of glyoxalase 1 deficiency,
compared to wild-type controls, and decreased weight gain in
glyoxalase 1-overexpressing transgenic mice, suggesting a
functional role of glyoxalase 1 and dicarbonyl stress in obesi-
ty. Increased methylglyoxal, dicarbonyl stress, in white adi-
pose tissue and liver may be a mediator of obesity and insulin
resistance and thereby a risk factor for development of type 2
diabetes and non-alcoholic fatty liver disease. Increased
methylglyoxal formation from glyceroneogenesis on adipose
tissue and liver and decreased glyoxalase 1 activity in obesity
likely drives dicarbonyl stress in white adipose tissue increas-
ing the dicarbonyl proteome and related dysfunction. The clin-
ical significance will likely emerge from on-going clinical
evaluation of inducers of glyoxalase 1 expression in over-
weight and obese subjects. Increased transcapillary escape rate
of albumin and increased total body interstitial fluid volume in
obesity likely makes levels of glycation of plasma protein
unreliable indicators of glycation status in obesity as there is
a shift of albumin dwell time from plasma to interstitial fluid,
which decreases overall glycation for a given glycemic
exposure.
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The obesity epidemic and related complications
In the last 30 years the causes of global premature death and
loss of productive life, as assessed in disability adjusted life
years reported by theWorld Health Organization, has changed
from communicable diseases in children towards non-
communicable diseases in adults. Impaired metabolic health
– development of insulin resistance leading to type 2 diabetes
(T2DM) is now a leading cause of disability-adjusted life
years. A major risk factor for this is being overweight and
obese (body mass index >25 kg/m2) in which insulin resis-
tance is a common feature and contributor to development of
T2DM [1]. The number of people who are overweight and
obese worldwide is now >2.1 billion, a prevalence of ca.
37 % in the adult population and 13 % in adolescents and
children in developing countries and 23 % in developed coun-
tries [2]. In 2010, overweight and obesity were estimated to
cause 3.4 million deaths worldwide. Most deaths attributable
to overweight and obesity are cardiovascular deaths; 36 % of
the increased risk of coronary heart disease (CHD) mortality
and 59 % of the increased risk of stroke mortality risk
associated with obesity was linked to increased blood
pressure and cholesterol, 14 % and 25 % of CHD and
stroke excess mortality were directly linked to glucose
and the remaining excess risk is unexplained [3]. A
further complication of overweight and obesity is non-
alcoholic fatty liver disease (NAFLD) leading to hepatic
steatosis (NASH), cirrhosis, liver failure and cancer [4].
Obesity-induced insulin resistance is a major driver of
development of T2DM and NAFLD. NAFLD affects
20–40 % of the population in Westernised countries
and will likely increase direct and indirect medical costs
by 25% in the next 5 years. There is an urgent requirement for
improved understanding of the risk factors of insulin resis-
tance, obesity and NAFLD and to guide interventions to de-
crease incidence and health impact.
Obesity and the glyoxalase system
Recent reviews have described the impact of obesity on the
glyoxalase system [5–8]. Herein consideration of the subject
is advanced with description of recent experimental studies
and findings with discussion of new underlying concepts, in-
terpretation and inferences.
Genetic factors, dietary factors and early-life nutrition in-
fluence risk of insulin resistance and obesity. A gene function-
ally linked to obesity and diabetes is the glyoxalase 1 (Glo-1)
gene, GLO-1 [9]. Glo-1 is part of the cytosolic glyoxalase
system present in the cytoplasm of all mammalian cells –
Fig. 1a. The glyoxalase system catalyses the metabolism of
methylglyoxal (MG) to D-lactate via the intermediate S-D-
lactoylglutathione and thereby suppresses the spontaneous
modification of proteins and DNA by MG forming advanced
glycation endproducts (AGEs). MG is the major precursor of
AGEs in vivo, modifying mainly arginine residues in
proteins to form hydroimidazolone MG-H1 - Fig. 1b, and
deoxyguanosine residues in DNA to form imidazopurinones
MGdG [10, 11] - Fig. 1c. Accumulation ofMG adducts would
otherwise cause protein dysfunction and mutagenesis. The
function of the glyoxalase system is the enzymatic defence
against MG glycation where Glo-1 catalyses the key step of
removing the potentially damaging MG. Periods of increased
MG concentration are called Bdicarbonyl stress^ produced by
increased MG formation and/or decrease Glo-1 activity.
In human subjects, GLO-1 was linked to anthropometric
measurements of obesity - upper-arm circumference and
supra-iliac skinfold thickness [12]. In mice, meta-analysis of
34 mouse cross-breeding experiments linked GLO-1 to body
weight [13]. Mice with a preference for a high energy-rich diet
without marked health impairment have a relatively high ex-
pression of Glo-1 [5]. In the mouse overeating model of obe-
sity, leptin mutant (ob/ob) mice, Glo-1 protein was decreased
80 % in the liver [14]. Recent conference reports described
increased weight gain on high fat diet (HFD)-fed mouse with
through-life expression of GLO-1 siRNA and mild Glo-1 defi-
ciency, compared to wild-type controls [15], and decreased
weight gain in Glo-1 overexpressing transgenic mice [16], sug-
gesting a functional role of Glo-1 and dicarbonyl stress in obe-
sity. We found increased MG concentration in hepatocyte-like
hepatoma G2 cells in vitro incubated with saturated fatty acid
and mono-unsaturated fatty acid, palmitic acid and oleic acid,
respectively, suggesting that fatty acid metabolism may drive
increased MG formation [17] – see below. HFD-fed wild-type
mice had increased MG-H1 content of heart and liver, as
judged by immunoassay [18]. Dicarbonyl stress may be a me-
diator of obesity and insulin resistance and thereby a risk factor
for development of T2DM and NAFLD.Moreover, in a mouse
model of hepatocellular carcinoma, Glo-1 was a tumour sup-
pressor protein [19]. Hence, decrease of Glo-1 activity and
hepatic dicarbonyl stress in NAFLD with progression to
NASH may also increase risk of hepatocellular carcinoma.
Obesity and dicarbonyl stress
Several studies have attempted to model dicarbonyl stress in
obesity by administration of exogenous MG. Difficulties
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performing such studies are: (i) lack of commercial availabil-
ity of suitable high purity MG, (ii) interference-free assay of
MG, and (iii) and judgement of an appropriate dose to admin-
ister. Commercial 40 % MG contains 9–17 mol% formalde-
hyde and many other compounds that potentially interfere in
studies of dicarbonyl stress [20]. Methods for preparation of
high purity MG and interference-free assay of MG have been
described [21, 22]. The flux of endogenous formation of MG
has been estimated at ca. 3–6 mg/kg (ca. 0.05 % glycolytic
rate, which we find relatively constant in many cell types)
[23]. Experimental studies have often used 10–20 fold
higher than this – which is likely similar to and exceeds
the upper limit of severe dicarbonyl stress of poorly-
controlled clinical diabetes and end stage renal disease
[24, 25]. MG formation of cells with GLUT1 glucose
transport increased only 2–3 fold in the high glucose con-
centration characteristic of T2DM and MG concentration in
blood of patients with T2DM showed a similar 2–3 fold in-
crease [24, 26].
Infusion of MG (60 mg/kg/day) into healthy rats induced
impaired glucose tolerance, decreased glucose transporter
GLUT-4, phosphoinositide-3-kinase activity, and insulin-
stimulated glucose uptake in adipose tissue [27].
Administration of exogenous MG (50–75 mg/kg, daily, i.p.)
induced insulin resistance in mice [28], inhibited insulin-
stimulated phosphorylation of protein kinase B and
extracellularly-regulated kinase, contributing to insulin resis-
tance in muscle cells [29]. It also inhibited insulin-induced
insulin receptor substrate tyrosine phosphorylation and phos-
phatidylinositol 3-kinase/protein kinase B pathway activation
in pancreatic beta-cells [30], increased free fatty acids,
hypoadiponectinemia, hypoxia and macrophage recruitment
of adipose tissue [31]. These levels of MG exposure also
arrested growth of rats, impaired renal function, induced hy-
percholesterolaemia and impaired vasodilation. There were
also degenerative changes in cutaneous capillaries with loss
of endothelial cells, basement membrane thickening, luminal
occlusion and inflammatory response – increased receptor for
AGE (RAGE), interleukin-1ß, tumour necrosis factor-α and
connective tissue growth factor in medial layers of arteries,
and transforming growth factor-ß in glomerular tufts, tubular
epithelial cells and interstitial endothelial cells [32]. These
MG administration models to date, therefore, explore features
of MG intoxication. Some of the features produced may be
similar to those developing in obesity – although they are
likely markedly less severe.
Moderate dicarbonyl stress in clinical obesity
To investigate dicarbonyl stress in clinical obesity we recruit-
ed obese and non-obese healthy human subjects and placed
them on an isocaloric diet for 2 weeks. Blood samples were
collected after overnight fasting and plasma prepared. Plasma
MGwas determined by stable isotopic dilution analysis liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
[22] and plasmaD-lactate concentration by endpoint enzymat-
ic assay [33]. Plasma MG was increased 35 % in obese sub-
jects and D-lactate was increased ca. 2-fold – Table 1. Plasma
MG levels were intermediate between those found in non-
obese healthy subjects and patients with type 1 or type 2
diabetes [22, 34, 35], suggesting clinical obesity is a state of
moderate dicarbonyl stress. Plasma D-lactate levels, a surro-
gate and qualitative indicator of MG flux, also supported this
[24, 35, 36] and suggest the flux of formation of MG is
increased in obesity. (D-Lactate is metabolised in human
subjects [37]). The MG-H1 residue content of plasma
protein was determined in obese and non-obese subjects
by exhaustive enzymatic hydrolysis of plasma protein
and MG-H1 detection and quantitation by and stable
isotopic dilution analysis LC-MS/MS [38] and no significant
difference was found.
Fig. 1 Biochemistry of dicarbonyl stress. a Metabolism of MG by the glyoxalase system. b Formation of hydroimidazolone MG-H1 from arginine
residues. c Formation of imidazopurinone MGdG in DNA. Adduct residue is shown with guanyl base only
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Estimates of MG and in white adipose tissue (WAT) in
experimental models of overfeeding, HFD fed mice, were
ca. 5000 nmol per g tissue versus ca. 2000 nmol per g tissue
in controls – equivalent to ca. 5 mM and 2 mM MG, respec-
tively [39]. Our estimates of MG in WAT of the same exper-
imental model by the reference protocol [22] are markedly
lower (mean ± SD): 2.91 ± 0.98 (n = 7) versus 1.47 ± 0.65
(n = 8, P < 0.01); equivalent to ca. 3 and 1.5 μM, respectively.
We also found markedly lower levels of glyoxal in WAT but
similar levels of 3-deoxyglucosone (Masania, J., Rabbani, N.,
Rossmeisl, M., Kopecky, J. and Thornalley, P.J.; unpublished
observations). Mathematical modelling of MG formation
and protein glycation in mouse tissue predicted MG
concentrations in the 1–2 μM range in normal metabo-
lism and are likely increased 2–3 fold in obesity [22].
Hence markedly higher estimates are not sustainable
metabolically and may have been caused by interference –
MG and glyoxal formation in pre-analytic processing.
Trichloroacetic acid deproteinization and azide blocking of
acid-stable peroxidase is required to avoid overestimation of
MG and glyoxal in mouse tissues [40]. This requires further
investigation.
Plasma protein glycation adducts as reporters
of glycation exposure in obesity
Glycated albumin
In clinical obesity as insulin resistance develops, there is pro-
gressive decline in glycemic control with impaired fasting and
postprandial hyperglycemia – as detected by continuous glu-
cose monitoring. There is a moderate increase in glycated
hemoglobin (A1C) as prediabetes develops [41] but surpris-
ingly there is often a decrease in glycated albumin with in-
creased BMI although A1C is increased. This is found both in
obese adults and children [42, 43] and lower than expected
glycated albumin in obesity also extends into the patients with
T2DM [43]. The steady-state level of albumin glycation in
plasma depends on the increased glucose concentration in
plasma and duration over which it occurs, and also the resi-
dence time of albumin in the plasma compartment – as judged
by the albumin transcapillary escape rate (TER). Until degrad-
ed with a half-life of ca. 20 days [44], albumin cycles from
plasma into interstitial fluid, lymph and returns to plasma –
with some leakage through renal glomeruli and return to ve-
nous circulation by the renal albumin retrieval pathway [45].
The rate of glycation by glucose normally is 4-fold higher in
the plasma compared to interstitial fluid so that decrease in
dwell time in plasma by increased TER may decrease
glycation without change in plasma glucose concentration
[45, 46] – Fig. 2. The rate of glycation of albumin by glucose,
rGlycation, is directly proportional to the concentration of glu-
cose and the concentration of albumin; rGlycation = kGlycation
[Glucose][Albumin], where kGlycation is the rate constant for
glycation of albumin by glucose. The concentrations of albu-
min and glucose are 2.7-fold and 1.4 fold higher in plasma
than interstitial fluid, which multiplied together indicate that
the rate of glycation by glucose normally is 3.8 fold or ca. 4-
fold higher in the plasma compared to interstitial fluid.
Table 1 Subject characteristics
Variable Non-obese Obese
N 18 29
Age (years) 50 ± 10 48 ± 11
Gender (M/F) 3/15 7/22
BMI (kg/m2) 27.8 ± 1.3 34.3 ± 3.3***
Systolic BP (mmHg) 125 ± 10 133 ± 21
Diastolic BP (mmHg) 79 ± 10 86 ± 10*
Hypertension (Y/N) 4/14 13/16
Fasting plasma glucose (mM) 5.1 ± 0.6 5.2 ± 0.6
Plasma MG (nM) 181 ± 61 245 ± 123*
Plasma protein MG-H1
(mmol/mol arg)
0.266 ± 0.105 0.264 ± 0.087
Plasma D-lactate (μM) 6.5 (2.4–13.7) 15.9 (10.0–20.2)*
Data are mean ± SD or median (lower – upper quartile). Significance: *
and ***,P < 0.05 andP < 0.001, respectively (t-test for parametric data or
Mann-Whitney U test for non-parametric data). Healthy human subjects
were recruited at the Department of Clinical Biochemistry, Jagiellonian
University Medical College, Krakow, Poland, after written informed con-
sent. Inclusion criteria were: age 25–65 years, BMI - > 30–40 kg/m2
(obese) or <30 kg/m2 (all except onewere overweight). Exclusion criteria
were any co-morbidity and any medication for dysglycaemia or
dyslipidaemia. Subjects were placed on a diet of 2300–2400 kcal/day
(isocaloric diet) for 2 weeks prior to blood sampling. Peripheral venous
blood samples were collected using EDTA as anticoagulant. Blood cells
were sedimented by centrifugation (2000 g, 10 min) and plasma removed
and retained for analysis. The study was approved by Jagiellonian
University Bioethical Committee (Ref. KBET/82/B/2009 of 25 June
2009). Plasma and red blood cells were stored at -80 °C until analysis.
The experiments conformed to the principles set out in the WMA
Declaration of Helsinki
Fig. 2 Glycation of albumin by glucose – glycation kinetics and
dynamics in vascular and extravascular compartments. Physiological
data from [45, 46]. Relative glycation kinetics deduced from:
rGlycation = k [Glucose][albumin], k is the glycation rate constant and
assuming rGlycation in the plasma compartment =100 %
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Albumin TER is increased by hypertension (from 5.6 % per
hour to 7.6 % per h) and plasma volume decreases by up to
10 % [47]. It is also increased in overweight/obese subjects
with metabolic syndrome [48]. Obesity also increases the total
body interstitial fluid volume [49]. This suggests that the ex-
planation for decreased plasma glycated albumin in obesity
with increased glucose exposure, as indicated by decreased
glycated albumin/A1C ratio, may be due to a shift of albumin
residence time from plasma to interstitial fluid in favour of the
latter. This suggests glycated albumin is an unreliable marker
of glycemic control in obesity.
The rate of degradation of albumin in obesity and diabetes
may also influence the level of glycated albumin if changed.
In obese subjects and patients with diabetes, with normal renal
function, the synthesis of albumin and plasma concentration
of albumin are unchanged from those of lean healthy controls,
suggesting that the rate of degradation of albumin is also nor-
mal [50, 51]. In experimental diabetes early studies of Baynes
and co-workers and others showed that the rate of degradation
of albumin was not increased but slightly lower in
streptozotocin-induced diabetic rats than in healthy controls
[52, 53]. So there is no evidence that an increased rate of
albumin degradation that contributes to decreased glycated
albumin or AGE-modified albumin in obesity and diabetes.
This may change, however, with impaired renal function with
increased urinary loss of albumin and compensatory increased
albumin synthesis [54].
AGEs in plasma/serum protein in obesity
A shift of albumin residence time from plasma to interstitial
fluid may also influence AGEs. Nε-Carboxymethyl-lysine
(CML) residue content of serum protein was inversely linked
to BMI and body fat mass [55, 56]. In studies where plasma
early glycated (glycated albumin), CML and florescent AGE
content were determined, all were decreased in obese subjects
compared to controls [57]. Decrease of CML residue content
of plasma protein in obesity was confirmed in an independent
study and association with central obesity and inflammation
[58]. Decreased CML residue content of plasma protein in
obesity has been explained as due to enlargement of adipose
tissue mass in obesity [59] and a contributory feature to this is
likely decreased glycation of albumin due to the shift of albu-
min from plasma to interstitial fluid. An association with in-
flammation is also expected as albumin TER increases with
increased capillary permeability in vascular inflammation
[60]. Decreased residence time of albumin in the vascular
lumen in obese subjects may also explain herein how plasma
MG is increased without increase in MG-H1 residue content
of plasma protein in our study –Table 1. This is supported by a
recent study with a Glo-1 inducer where plasma MG concen-
tration and whole body endogenous formation of MG-H1
adduct flux was decreased without decrease in plasma protein
MG-H1 residue content. This was attributed to improved vas-
cular function, decreased albumin TER and increased plasma
dwell time of albumin with Glo-1 inducer intervention [61].
Given this, it is also likely that plasma protein AGE content in
obesity is not a reliable indicator of AGE tissue exposure – as
found previously [59].
Source of dicarbonyl stress in obesity and its likely
effects
Our finding of increased plasmaMG and D-lactate concentra-
tions in obese human subjects compared to non-obese subjects
on an isocaloric diet suggests the source of dicarbonyl stress in
obesity is not of dietary origin. Indeed, recent studies of met-
abolic transit of MG indicate that dietary MG is metabolised
and/or reacts with protein in the intestinal lumen and has lim-
ited bioavailability [62]. Moreover the insulin resistance in
obesity suggests the usually dominant source of MG forma-
tion from increased flux through anaerobic glycolysis may not
be increased. Triosephosphates, however, are not limited to
intermediates of anaerobic glycolysis but are also intermedi-
ates of glyceroneogenesis and gluconeogenesis. Increased
glyceroneogenesis is associated with adipocyte expansion in
obesity supporting increased fatty acid esterification for tri-
glyceride deposition [63]. Most triglyceride synthesis in-
volves glyceroneogenesis via triosephosphate intermediates
[64]. Glyceroneogenesis is not limited, however, because it
uses pyruvate as the carbon source, which has unrestricted
entry and metabolism into major cell types experiencing insu-
lin resistance – such as adipocytes, hepatocytes and skeletal
muscle cells. As flux of glyceroneogenesis increases to sup-
port triglyceride synthesis, there is proportionate increase in
MG formation by related increase in flux of triosephosphate
formation. Most triosephosphate intermediates go on to form
glycero-l-3-phosphate but with 0.05 % of triosephosphate
degrading to MG, when the flux through glyceroneogenesis
increases then concomitantly the flux of MG formation also
increases. Increased glyceroneogenesis, therefore, is likely a
major driver of increased MG formation in obesity – Fig. 3.
There is no inconsistency with previous findings of in-
creased MG from red blood cells in high glucose concentra-
tion as therein MG is formed from increased concentrations of
triosephosphates driven by increased uptake and metabolism
of glucose in anaerobic glycolysis. Red blood cells do not
suffer impaired glucose metabolism in insulin resistance.
MG is mainly formed non-enzymatically from the same pre-
cursors in all cells and tissues – triosephosphates – but the
pathways that sustain triosephosphate concentrations differ
and may be multiple in cells and tissues.
In experimental models of obesity there is evidence of de-
creased Glo-1 activity in visceral adipose tissue [16]. Human
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Glo-1 protein is a dimer of 42 kDa. It undergoes post-
translational modifications: C139 may form a mixed disulfide
with GSH, inhibiting Glo-1 activity in vitro. Glo-1 may be S-
nitrosylated on C139 and is a substrate for calcium, calmodulin-
dependent protein kinase II, with phosphorylation at T107.
There is acetylation at K148 [65] and likely de-acetylation by
cytosolic sirtuin-2 [66]. Glo-1 down regulation in obesity may
be driven through hypoxia signalling by hypoxia-inducible fac-
tor-1α (HIF1α), which down-regulates Glo-1 expression [67].
As adipose tissue expands, interstitial oxygen tension de-
creases. HIF1α protein is highly enriched in expanding adipo-
cytes as it drives increased adipose tissue vascularization.
Adipocyte-specific deletion of HIF1α decreased HFD–induced
adipose tissue inflammation and insulin resistance [68].
Increased MG formation by glyceroneogenesis and decreased
Glo-1 expression through HIF1α signalling therefore provides
the conditions for dicarbonyl stress in obesity.
The consequences of dicarbonyl stress in white adipose
tissue (WAT) are unknown but contribute to insulin resistance.
Obesity is associated with decreased activity of the insulin
sensitising effects of fibroblast growth factor-21 (FGF21)
due to down regulation of the FGF21 receptor cofactor β-
Klotho [69]. Decreased FGF21 activity also impairs
uncoupling protein-1 expression in brown adipose tissue, en-
ergy utilisation for thermogenesis [70] and facilitating fat de-
position and weight gain. MG-driven protein glycation de-
creased expression of β-Klotho [71] and thereby likely con-
tributes to insulin resistance. Decreased β-Klotho is also per-
missible for induction of pro-inflammatory mediators, inter-
leukin-8, monocyte chemotactic protein-1, intracellular adhe-
sion molecule-1 and receptor for AGEs, RAGE [71].
Overexpression of Glo-1 prevented insulin resistance and in-
flammation in HFD-fed mice, suggesting a functional role of
dicarbonyl stress in obesity. This will be tested clinically by
evaluation of Glo-1 inducer therapeutics.
In dicarbonyl stress there is increased protein glycation by
MG. MGmodification is directed to arginine residues often at
functional sites of proteins and leads to functional change or
inactivation. Protein targets of MGmodification are called the
dicarbonyl proteome [72]. The extent of protein glycation by
MG is usually 1–2 % but low level increases can have pro-
found physiological effect [73]. Examples are: MG modifica-
tion of mitochondrial proteins, which increases formation of
reactive oxygen species and oxidative damage [74]; modifi-
cation of extracellular matrix proteins produces endothelial
cell detachment with exposure of the sub-endothelium, plate-
let activation and thrombosis [72]; and modification of apoli-
poprotein B100 of low density lipoprotein (LDL) producing a
atherogenic transformation to small, dense LDL [75].
Moreover, MG modification of proteins stimulates their pro-
teolysis, decreasing protein half-life and thereby concentra-
tions of the unmodified protein unless there is compensatory
increased transcription - as found for apolipoprotein A1 of
high density lipoprotein [76]. In relation to this, increasing
endogenous MG by Glo-1 silencing in aortic endothelial cells
changed expression of >400 genes [77]. Dicarbonyl stress,
therefore, has proteome, dicarbonyl proteome and tran-
scriptome signatures.
Increased MG formation from glyceroneogenesis on adi-
pose tissue and liver and decreased Glo-1 activity in obesity
likely drives dicarbonyl stress in WAT increasing the
dicarbonyl proteome and related dysfunction. The functional
significance of this is indicated by protection from insulin
resistance, inflammation and weight gain in Glo-1 transgenic
mice in experimental model of over-eating induced obesity.
The clinical significance will likely emerge from on-going
clinical evaluation of inducers of Glo-1 expression in over-
weight and obese subjects – for example, Clinicaltrials.gov;
NCT02095873.
Summary
MG metabolism and the glyoxalase system are disturbed in
obesity leading to dicarbonyl stress. Functional genomics
studies with Glo-1 in the overfeeding model of HFD-fed mice
Fig. 3 Increased formation of
methylglyoxal in the triglyceride/
free fatty acid cycle. Percentage
flux of glyceroneogenesis in tri-
glyceride formation in liver and
adipose tissue is from [64]
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suggest dicarbonyl stress is a risk factor for health impairment
and complications of obesity. Likely drivers of dicarbonyl
stress in obesity are: increased formation of MG from in-
creased glycerogenesis in triglyceride synthesis and decreased
Glo-1 expression and activity through hypoxia and inflamma-
tory signalling. A recent clinical intervention study with a
Glo-1 inducer produced a profound improvement of insulin
resistance, improved glycemic control and arterial function
and decreased vascular inflammation, suggesting that Glo-1
inducer therapeutics may have a future key role in alleviating
complications of obesity. Increased albumin TER in obesity
associated with increased fat mass, hypertension and inflam-
mation suggest glycated albumin is not a reliable measure of
glycemic control and formation of AGEs in obesity.
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